Data as of Dec 26
| +0.11 / +2.37%|
The 7 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 8.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +68.42% increase from the last price of 4.75.
The current consensus among 9 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.